Pharmacokinetics and concentration-effect relationship of oral LSD in humans
This double-blind, placebo-controlled, within-subjects study (n=16) evaluated the pharmacokinetic profile of oral LSD (200 μg) in humans. The analysis found that the acute subjective and sympathomimetic effects of LSD lasted for up to 12 hours and were closely linked to the plasma concentrations over time and showed no acute tolerance. This is the first such study and can act as a potential reference for the assessment of intoxication with LSD.
Authors
- Yasmin Schmid
- Patrick Dolder
- Matthias Liechti
Published
Abstract
Background
The pharmacokinetics of oral lysergic acid diethylamide are unknown despite its common recreational use and renewed interest in its use in psychiatric research and practice.
Methods
We characterized the pharmacokinetic profile, pharmacokinetic-pharmacodynamic relationship, and urine recovery of lysergic acid diethylamide and its main metabolite after administration of a single oral dose of lysergic acid diethylamide (200 μg) in 8 male and 8 female healthy subjects.
Results
Plasma lysergic acid diethylamide concentrations were quantifiable (>0.1ng/mL) in all the subjects up to 12 hours after administration. Maximal concentrations of lysergic acid diethylamide (mean±SD: 4.5±1.4ng/mL) were reached (median, range) 1.5 (0.5-4) hours after administration. Concentrations then decreased following first-order kinetics with a half-life of 3.6±0.9 hours up to 12 hours and slower elimination thereafter with a terminal half-life of 8.9±5.9 hours. One percent of the orally administered lysergic acid diethylamide was eliminated in urine as lysergic acid diethylamide, and 13% was eliminated as 2-oxo-3-hydroxy-lysergic acid diethylamide within 24 hours. No sex differences were observed in the pharmacokinetic profiles of lysergic acid diethylamide. The acute subjective and sympathomimetic responses to lysergic acid diethylamide lasted up to 12 hours and were closely associated with the concentrations in plasma over time and exhibited no acute tolerance.
Conclusions
These first data on the pharmacokinetics and concentration-effect relationship of oral lysergic acid diethylamide are relevant for further clinical studies and serve as a reference for the assessment of intoxication with lysergic acid diethylamide.
Research Summary of 'Pharmacokinetics and concentration-effect relationship of oral LSD in humans'
Introduction
Dolder and colleagues frame lysergic acid diethylamide (LSD) as a prototypical hallucinogen with continuing recreational use and renewed interest for psychiatric research. The authors note that despite this interest, the pharmacokinetics (PK) of orally administered LSD in humans remain poorly characterised: prior data are limited to small intravenous studies and sparse oral sampling that did not permit full PK parameter estimation. This study therefore set out to define the single-dose pharmacokinetic profile of oral LSD (200 µg) in healthy men and women, to relate plasma concentrations to acute subjective and physiological effects (PK-pharmacodynamic relationship), and to quantify urinary excretion of LSD and its main metabolite 2-oxo-3-hydroxy-LSD (O-H-LSD). The aim was to provide data useful for clinical research and forensic assessment of LSD intoxication.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Dolder, P. C., Schmid, Y., Haschke, M., Rentsch, K. M., & Liechti, M. E. (2016). Pharmacokinetics and concentration-effect relationship of oral LSD in humans. International Journal of Neuropsychopharmacology, 19(1), pyv072. https://doi.org/10.1093/ijnp/pyv072
References (3)
Papers cited by this study that are also in Blossom
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Cited By (46)
Papers in Blossom that reference this study
McCulloch, D. E-W., Larsen, K., Johansen, A. et al. · MedRvix (2025)
Arikci, D., Holze, F., Mueller, L. et al. · Clinical Pharmacology and Therapeutics (2025)
Morse, D. J., Jeong, S. H., Murphy, R. J. et al. · Journal of Psychopharmacology (2025)
Rosas, F. E., Mediano, P. A. M., Timmermann, C. et al. · Biorxiv (2023)
Friederike, H., Liechti, M. E., Holze, F. et al. · British Journal of Clinical Pharmacology (2023)
Henríquez-Hernández, L. A., Rojas-Hernández, J., Quintana-Hernández, D. J. et al. · Toxics (2023)
Family, N., Hendricks, P. S., Williams, L. T. J. et al. · Journal of Psychopharmacology (2022)
Holze, F., Caluori, T. V., Vizeli, P. et al. · Psychopharmacology (2021)
Madsen, M. K., Stenbaek, D. S., Arvidsson, A. et al. · European Neuropsychopharmacology (2021)
Holze, F., Avedisian, I., Varghese, N. et al. · Frontiers in Pharmacology (2021)
Show all 46 papersShow fewer
Vizeli, P., Straumann, I., Holze, F. et al. · Scientific Reports (2021)
Olbrich, S., Preller, K. H., Vollenweider, F. X. · Psychophysiology (2021)
Aday, J. S., Davis, A. K., Mitzkovitz, C. M. et al. · ACS Pharmacology and Translational Science (2021)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)
Zhang, D. Z., Holze, F., Liechti, M. E. et al. · Clinical Pharmacology and Therapeutics (2020)
Holze, F., Vizeli, P., Ley, L. et al. · Neuropsychopharmacology (2020)
Schmid, Y., Gasser, P., Oehen, P. et al. · Journal of Psychopharmacology (2020)
Greb, A. C., Vargas, M. V., Duim, W. C. et al. · ACS Pharmacology and Translational Science (2020)
Kuypers, K. P. C. · Therapeutic Advances in Psychopharmacology (2020)
Family, N., Maillet, E. L., Williams, L. T. J. et al. · Psychopharmacology (2019)
Bershad, A. K., Schepers, S. T., Bremmer, M. P. et al. · Biological Psychiatry (2019)
Luethi, D., Hoener, M. C., Krähenbühl, S. et al. · Biochemical Pharmacology (2019)
Holze, F., Duthaler, U., Vizeli, P. et al. · British Journal of Clinical Pharmacology (2019)
Libânio Osório Marta, R. F. · Drug Metabolism Reviews (2019)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Nichols, D. E. · ACS Chemical Neuroscience (2018)
Nichols, D. E., Grob, C. S. · Forensic Science International (2018)
Sumiyoshi, T., Kraehenmann, R., Pokorny, D. et al. · Frontiers in Pharmacology (2017)
Schmidt, A., Müller, F., Lenz, C. et al. · Psychological Medicine (2017)
Lenz, C., Dolder, P. C., Lang, U. E. et al. · Acta Psychiatrica Scandinavica (2017)
Schmid, Y., Liechti, M. E. · Psychopharmacology (2017)
Kraehenmann, R. · Current Neuropharmacology (2017)
Liechti, M. E., Dolder, P. C., Grünblatt, E. et al. · Frontiers in Pharmacology (2017)
Liechti, M. E. · Neuropsychopharmacology (2017)
Mueller, F., Lenz, C., Dolder, P. C. et al. · Translational Psychiatry (2017)
Vizeli, P., Liechti, M. E. · Journal of Psychopharmacology (2017)
Dolder, P. C., Schmid, Y., Steuer, A. E. et al. · Clinical Pharmacokinetics (2017)
Wacker, D., Wang, S., Mccorvy, J. D. et al. · Cell (2017)
Liechti, M. E., Dolder, P. C., Schmid, Y. · Psychopharmacology (2016)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Strajhar, P., Schmid, Y., Liakoni, E. et al. · Journal of Neuroendocrinology (2016)
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)
Rickli, A., Luethi, D., Reinisch, J. et al. · Neuropharmacology (2015)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.